Prostate Cancer Treatment and Research / Cancer, Stress, Anesthesia, and Immune Response / Pharmacological Receptor Mechanisms and Effects · Journal article

Recent advances in PSMA therapy - from beta to alpha

Annals of Nuclear Medicine · August 16, 2026

Expert Guidance Why this matters to you Expert discussion

A consensus or society position rather than new primary data.

AI Summary

This is a narrative review updating the state of PSMA radiotheranostic approaches for advanced prostate cancer management, covering both established beta-emitting and emerging alpha-emitting ligand-based therapies. The article synthesizes clinical trial evidence and recent developments to inform clinical and research practice, rather than presenting original efficacy or safety data.

What was studied

Narrative review. Patients with advanced prostate cancer.

Key findings

PSMA theranostics using beta-emitting ligands are firmly anchored in clinical guidelines for advanced prostate cancer management Recent developments include alpha-based approaches, particularly actinium-based, astatine-based, and lead-based radiopharmaceutical therapies

Safety

Recent developments include alpha-based approaches, particularly actinium-based, astatine-based, and lead-based radiopharmaceutical therapies

Who this may help

This review provides an evidence-based overview of PSMA radiotheranostic options ranging from established beta-emitting to emerging alpha-emitting approaches, intended to inform clinical decision-making and research directions in advanced prostate cancer management.

Plain-language summary

A narrative review article surveying established and emerging PSMA radiotheranostic approaches, synthesizing clinical trial evidence and recent developments for professional education rather than reporting original research findings.

Study design

As stated by the source record.

MethodsNarrative review

Clinical bottom line

Caveats

Source is a narrative review without reporting specific efficacy metrics, effect sizes, or comparative outcomes
No sample sizes, confidence intervals, p-values, or hazard ratios are provided for individual studies or therapies
The text does not detail the scope of literature reviewed, inclusion criteria, or systematic methods
Specific clinical trial results referenced are not detailed in the excerpt provided

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Review article; no primary study design reported.

Directness

moderate

Addresses clinical management of advanced prostate cancer with PSMA theranostics.

Consistency

insufficient

Source does not report comparative consistency across included studies.

Risk of bias

insufficient

Review article; no bias assessment methodology described.

Sample adequacy

insufficient

Narrative synthesis; no aggregate sample size or power calculation stated.

What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.

Source abstract

management of patients with advanced prostate cancer, firmly anchored in clinical guidelines [8].This article provides an update on established PSMA theranostics using beta-emitting ligands, based on major clinical trial results.It then continues with an overview of more recent developments in the field of PSMA radiotheranostics, focusing on alpha-based approaches, in particular on actinium-based and, subsequently, astatine-and leadbased radiopharmaceutical therapies (RPTs).

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Prostate Cancer Treatment and ResearchSophie C. SiegmundAdrien HolzgreveRudolf A. WernerCancer, Stress, Anesthesia, and Immune ResponsePharmacological Receptor Mechanisms and EffectsLiam Widjaja